

ERRATUM

Open Access



Erratum to: 'Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial'

Thomas P. Hellyer^{1*}, Niall H. Anderson², Jennie Parker³, Paul Dark⁴, Tina Van Den Broeck⁵, Suveer Singh⁶, Ronan McMullan⁷, Ashley M. Agus⁸, Lydia M. Emerson⁹, Bronagh Blackwood⁹, Savita Gossain¹⁰, Tim S. Walsh¹¹, Gavin D. Perkins¹², Andrew Conway Morris¹³, Daniel F. McAuley^{2,8,14} and A. John Simpson¹

Erratum

Unfortunately, the original version of this article [1] contained an error. There are two references in the text to the threshold for defining VAP as greater than 10^4 colony forming units/ml. These should read greater OR EQUAL to 10^4 colony forming units/ml. The error is in the abstract and in the intervention sections.

In the abstract, please replace:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at $>10^4$ colony forming units per millilitre (CFU/ml).

With the following correct version:

Patients with clinically suspected VAP undergo BAL and VAP is confirmed by growth of a potential pathogen at $\geq 10^4$ colony forming units per millilitre (CFU/ml).

In the Interventions, please replace:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at $>10^4$ colony forming units per ml (CFU/ml)(13).

With the following correct version:

VAP is confirmed by the widely used threshold of growth of a potential pathogen at $\geq 10^4$ colony forming units per ml (CFU/ml)(13).

Author details

¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. ²Centre for Population Health Sciences, University of Edinburgh, Medical School, Edinburgh, UK. ³Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK. ⁴Institute of Inflammation and Repair, University of

Manchester, Manchester Academic Health Sciences Centre & Intensive Care Unit, Salford Royal NHS Foundation Trust, Greater Manchester, UK. ⁵Becton Dickinson Biosciences, Erembodegem, Aalst, Belgium. ⁶Intensive Care Unit, Chelsea and Westminster Hospital, Imperial College London, London, UK. ⁷Department of Medical Microbiology, Kelvin Building, The Royal Hospitals, Belfast, UK. ⁸Northern Ireland Clinical Trials Unit, Elliot Dynes Building, The Royal Hospitals, Belfast, UK. ⁹Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK. ¹⁰Public Health Laboratory, Heart of England NHS Foundation Trust, Birmingham, UK. ¹¹MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK. ¹²University of Warwick and Heart of England NHS Foundation Trust, Coventry, UK. ¹³Division of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK. ¹⁴Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK.

Received: 30 August 2016 Accepted: 13 September 2016

Published online: 26 September 2016

Reference

1. Hellyer TP, Anderson NH, Jennie P, Paul D, Tina Van Den B, Suveer S, Ronan MM, Agus AM, Emerson LM, Bronagh B, Savita G, Walsh TS, Perkins GD, Conway Morris A, McAuley DF, Simpson AJ. Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial. *Trials*. 2016;17:318.

* Correspondence: t.p.hellyer@ncl.ac.uk

¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

Full list of author information is available at the end of the article